AltMountain

Matrix Capital Management Company, LP

Portsmouth, NH · CRD 160066
Hedge fund manager

Matrix Capital Management Company, LP is an SEC-registered investment adviser based in Portsmouth, NH that reports managing 1 hedge fund on Form ADV. It reports $2.3 billion in regulatory assets under management. Its private funds, of all types, hold $2.3 billion in gross assets. Over a longer period they returned an estimated +45.2% from Q3 2024 to Q1 2026, compared with +19.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$2.3 billionForm ADV Item 5.F
Gross assets of private funds
$2.3 billionAll private fund types, Form ADV
Hedge funds managed
12 private funds in total
Employees
7Form ADV Item 5.A
Registration
SEC-registered adviserCRD 160066
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 7 quarters+45.2%Q3 2024 – Q1 2026
S&P 500+19.5%Same quarters, price only
13F holdings$46.3 million1 positions, 2026-03-31
$96$121$145Q3 2024Q1 2025Q3 2025Q1 202613F est. $145S&P 500 $120
QuarterEst. 13F returnS&P 500
Q1 2026+5.3%-4.6%
Q4 2025+17.2%+2.4%
Q3 2025+13.5%+7.8%
Q2 2025+2.5%+10.4%
Q1 2025-2.9%-4.5%
Q4 2024+8.6%+2.1%
Q3 2024-4.1%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

Largest disclosed holdings

  • Aura Biosciences Inc$46.3 million

As of 2026-03-31, from 13F filing by Matrix Capital Management Company, LP. This is the firm’s most recent holdings report in the SEC data; it has not reported holdings for later quarters under this name.

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Aura Biosciences, Inc.13D amendment0%0May 11, 2026SEC.gov ↗
Zentalis Pharmaceuticals, Inc.13D amendment0%0Jan 2, 2026SEC.gov ↗
Maze Therapeutics, Inc.13G amendment3.5%1,653,684Nov 13, 2025SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 13, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

Fund
Gross assets
Minimum
Owners
Adviser
Matrix Capital Management Master Fund, L.P.
Cayman IslandsHedge fund
Gross assets$11B
Minimum$100K
Owners435
AdviserMatrix Capital Management Company, LP
Ayurmaya Capital Management Fund, LP
Delaware, United StatesPrivate equity fund
Gross assets$951M
Minimum$100K
Owners166
AdviserMatrix Capital Management Company, LP

As reported in the adviser's Form ADV filed Apr 5, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌‌⁠